S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
OTCMKTS:ADXS

Ayala Pharmaceuticals (ADXS) Stock Forecast, Price & News

$1.25
-0.02 (-1.57%)
(As of 06/7/2023 ET)
Compare
Today's Range
$1.25
▼
$1.27
50-Day Range
$0.65
▼
$1.28
52-Week Range
$0.65
▼
$4.50
Volume
9,676 shs
Average Volume
7,685 shs
Market Capitalization
$2.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort Interest

ADXS stock logo

About Ayala Pharmaceuticals (OTCMKTS:ADXS) Stock

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADXS Stock News Headlines

June 5, 2023 | finance.yahoo.com
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 3, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)
June 7, 2023 | Legacy Research (Affiliate) (Ad)
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
May 30, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Upgraded to "Buy" by LADENBURG THALM/SH SH
May 28, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com
May 28, 2023 | americanbankingnews.com
Short Interest in Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) Rises By 73.3%
May 25, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
June 7, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 23, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)
May 22, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com
May 20, 2023 | health.usnews.com
Armando Ayala
May 13, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com
May 12, 2023 | americanbankingnews.com
Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) Sees Large Decrease in Short Interest
May 7, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com
April 28, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com
April 27, 2023 | finance.yahoo.com
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 21, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Coverage Initiated at StockNews.com
April 13, 2023 | uk.finance.yahoo.com
Ayala Pharmaceuticals, Inc. (ADXS)
April 12, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Receives New Coverage from Analysts at StockNews.com
April 12, 2023 | forbes.com
Hubei Biocause Pharmaceutical
April 12, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Now Covered by StockNews.com
April 10, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Now Covered by Analysts at StockNews.com
April 7, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Earns Sell Rating from Analysts at StockNews.com
April 6, 2023 | americanbankingnews.com
Ayala Pharmaceuticals (OTCMKTS:ADXS) Coverage Initiated by Analysts at StockNews.com
April 5, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)
April 4, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)
See More Headlines

ADXS Price History

ADXS Company Calendar

Last Earnings
9/09/2021
Today
6/07/2023
Fiscal Year End
10/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ADXS
CUSIP
N/A
CIK
1100397
Web
www.advaxis.com
Phone
(609) 452-9813
Fax
609-452-9818
Employees
14
Year Founded
2002

Profitability

EPS (Most Recent Fiscal Year)
($8.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,360,000.00
Net Margins
N/A
Pretax Margin
-5,723.60%
Return on Equity
-57.87%
Return on Assets
-51.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.19
Quick Ratio
11.18

Sales & Book Value

Annual Sales
$3.24 million
Price / Sales
0.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.01 per share
Price / Book
0.10

Miscellaneous

Outstanding Shares
1,816,000
Free Float
1,810,000
Market Cap
$2.31 million
Optionable
Optionable
Beta
2.43

Social Links


Key Executives

  • Ken Berlin
    President, Chief Executive Officer & Director
  • Igor Gitelman
    VP-Finance, Chief Financial & Accounting Officer
  • Andres A. Gutiérrez
    Chief Medical Officer & Executive Vice President
  • Michael Grace
    Vice President-Technical Operations

Key Competitors

View All Competitors













ADXS Stock - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADXS shares.
View ADXS analyst ratings or view top-rated stocks.

How have ADXS shares performed in 2023?

Ayala Pharmaceuticals' stock was trading at $1.20 at the beginning of 2023. Since then, ADXS shares have increased by 5.8% and is now trading at $1.27.
View the best growth stocks for 2023 here.

Are investors shorting Ayala Pharmaceuticals?

Ayala Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,200 shares, an increase of 73.3% from the April 30th total of 3,000 shares. Based on an average trading volume of 12,900 shares, the days-to-cover ratio is currently 0.4 days.
View Ayala Pharmaceuticals' Short Interest.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) posted its earnings results on Thursday, September, 9th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.02. The biotechnology company earned $0.25 million during the quarter.

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ADXS."

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ayala Pharmaceuticals' stock price today?

One share of ADXS stock can currently be purchased for approximately $1.27.

How much money does Ayala Pharmaceuticals make?

Ayala Pharmaceuticals (OTCMKTS:ADXS) has a market capitalization of $2.31 million and generates $3.24 million in revenue each year. The biotechnology company earns $-14,360,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The official website for the company is www.advaxis.com. The biotechnology company can be reached via phone at (609) 452-9813, via email at ir@advaxis.com, or via fax at 609-452-9818.

This page (OTCMKTS:ADXS) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -